Neuren Pharmaceuticals | NEU

Stock Price
20.48
Daily Change
0.50 2.50%
Monthly
20.40%
Yearly
51.03%
Q3 Forecast
20.37

Peers Price Chg Day Year Date
Avita Medical 1.34 0.01 0.75% -48.46% Sep/05
Tectonic Therapeutic 16.80 -0.47 -2.72% -8.50% Sep/05
Clinuvel Pharmaceuticals 11.28 0.71 6.72% -23.37% Sep/05
Genetic Signatures 0.28 0.01 1.82% -60.00% Sep/05
Ionis Pharmaceuticals 61.23 1.88 3.17% 30.58% Sep/05
Dianthus Therapeutics 26.50 1.84 7.46% -0.45% Sep/05
Medical Developments International 0.58 -0.01 -0.86% 36.90% Sep/05
Neuren Pharmaceuticals 20.48 0.50 2.50% 51.03% Sep/05
Organon & Co 10.38 0.70 7.23% -49.40% Sep/05
Paradigm Biopharmaceuticals 0.28 0.02 5.66% 19.15% Sep/05
PYC Therapeutics 1.25 -0.02 -1.57% 8.70% Sep/05
Starpharma Holdings 0.13 0 0% 36.84% Sep/05
Telix Pharmaceuticals 13.80 0.03 0.22% -22.21% Sep/05
Viatris 10.50 0.17 1.65% -6.87% Sep/05
Xeris Pharmaceuticals 7.85 -0.04 -0.51% 212.75% Sep/05
Alaunos Therapeutics 2.16 0 0% -10.74% Sep/05

Indexes Price Day Year Date
ASX200 8871 44.67 0.51% 10.70% Sep/05

Neuren Pharmaceuticals Ltd traded at 20.48 this Friday September 5th, increasing 0.50 or 2.50 percent since the previous trading session. Looking back, over the last four weeks, Neuren Pharmaceuticals gained 20.40 percent. Over the last 12 months, its price rose by 51.03 percent. Looking ahead, we forecast Neuren Pharmaceuticals Ltd to be priced at 20.37 by the end of this quarter and at 20.04 in one year, according to Trading Economics global macro models projections and analysts expectations.

Neuren Pharmaceuticals Limited is an Australia-based biopharmaceutical company developing therapies for neurodevelopmental disorders. The Company is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The Company has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.